NASDAQ:CRVS - Corvus Pharmaceuticals Stock Price, Price Target & More

$10.56 -0.09 (-0.85 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$10.56
Today's Range$10.52 - $11.12
52-Week Range$7.42 - $17.64
Volume65,047 shs
Average Volume99,610 shs
Market Capitalization$224.35 million
P/E Ratio-3.88
Dividend YieldN/A
Beta-2.81

About Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals logoCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520

Debt

Debt-to-Equity RatioN/A
Current Ratio10.18%
Quick Ratio10.18%

Price-To-Earnings

Trailing P/E Ratio-3.88
Forward P/E Ratio-3.35
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.03 per share
Price / Book2.62

Profitability

EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-55.45%
Return on Assets-50.36%

Miscellaneous

Employees55
Outstanding Shares21,070,000

How to Become a New Pot Stock Millionaire

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals (NASDAQ:CRVS) posted its quarterly earnings results on Thursday, March, 1st. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.19. View Corvus Pharmaceuticals' Earnings History.

What price target have analysts set for CRVS?

3 Wall Street analysts have issued 12-month price objectives for Corvus Pharmaceuticals' stock. Their forecasts range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Corvus Pharmaceuticals.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decrease in short interest during the month of March. As of March 15th, there was short interest totalling 873,065 shares, a decrease of 22.1% from the February 28th total of 1,120,698 shares. Based on an average daily trading volume, of 234,689 shares, the short-interest ratio is presently 3.7 days. Currently, 7.6% of the company's shares are short sold.

Who are some of Corvus Pharmaceuticals' key competitors?

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard A. Miller M.D., Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 67)
  • Dr. Peter A. Thompson M.D., FACP, Co-Founder and Director (Age 58)
  • Mr. Leiv Lea, CFO & Chief Bus. Officer (Age 64)
  • Dr. Joseph J. Buggy Ph.D., Co-Founder and Strategic Advisor (Age 51)
  • Mr. Daniel W. Hunt, Sr. VP & Chief Bus. Officer

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Has Corvus Pharmaceuticals been receiving favorable news coverage?

News stories about CRVS stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.04 on Accern's scale. They also gave news headlines about the company an impact score of 45.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ORBIMED ADVISORS LLC (20.47%) and ADAMS STREET PARTNERS LLC (15.50%). Company insiders that own Corvus Pharmaceuticals stock include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $10.56.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $224.35 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]


MarketBeat Community Rating for Corvus Pharmaceuticals (CRVS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Corvus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 89.39%. The high price target for CRVS is $26.00 and the low price target for CRVS is $14.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.00$21.6667$21.6667$21.6667
Price Target Upside: 89.39% upside140.74% upside66.67% upside66.67% upside

Corvus Pharmaceuticals (NASDAQ:CRVS) Consensus Price Target History

Price Target History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2018CowenReiterated RatingBuyLowView Rating Details
8/23/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$14.00HighView Rating Details
8/8/2017WedbushReiterated RatingOutperform$26.00MediumView Rating Details
4/5/2017Cantor FitzgeraldReiterated RatingBuy$25.00HighView Rating Details
6/2/2016BTIG ResearchInitiated CoverageBuyN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Corvus Pharmaceuticals (NASDAQ:CRVS) Earnings History and Estimates Chart

Earnings by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS) Earnings Estimates

2018 EPS Consensus Estimate: ($3.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.71)($0.71)($0.71)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.80)($0.80)($0.80)

Corvus Pharmaceuticals (NASDAQ CRVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018Q4 2017($0.7650)($0.58)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.8140)($0.62)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.76)($0.73)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.79)ViewN/AView Earnings Details
3/10/201712/31/2016($0.52)($0.55)ViewN/AView Earnings Details
11/3/2016Q3 2016($0.45)($0.51)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.36)($0.43)ViewN/AView Earnings Details
5/5/2016Q1 2016($5.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corvus Pharmaceuticals (NASDAQ:CRVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 46.40%
Institutional Ownership Percentage: 82.71%
Insider Trading History for Corvus Pharmaceuticals (NASDAQ:CRVS)
Institutional Ownership by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018Adams Street Partners LlcMajor ShareholderBuy588,235$8.50$4,999,997.504,420,516View SEC Filing  
3/12/2018Richard A Md MillerCEOBuy100,000$8.50$850,000.00View SEC Filing  
11/20/2017Richard A Md MillerCEOBuy10,000$10.79$107,900.00View SEC Filing  
6/23/2017Holdings A/S NovoMajor ShareholderBuy20,000$10.95$219,000.003,244,046View SEC Filing  
6/13/2017Richard A Md MillerInsiderBuy25,000$9.88$247,000.00View SEC Filing  
6/24/2016Orbimed Advisors LlcDirectorBuy1,000$12.98$12,980.00View SEC Filing  
6/21/2016Orbimed Advisors LlcDirectorBuy38,383$12.75$489,383.25View SEC Filing  
6/16/2016Orbimed Advisors LlcDirectorBuy20,000$12.35$247,000.00View SEC Filing  
6/10/2016Peter A ThompsonDirectorBuy50,000$12.96$648,000.00View SEC Filing  
5/20/2016Orbimed Advisors LlcDirectorBuy4,716$13.09$61,732.44View SEC Filing  
5/19/2016Peter A ThompsonDirectorBuy6,800$11.77$80,036.00View SEC Filing  
5/13/2016Richard A Md MillerCEOBuy30,300$10.00$303,000.00View SEC Filing  
5/12/2016A/S NovoMajor ShareholderBuy70,000$10.00$700,000.003,224,046View SEC Filing  
3/29/2016Adams Street Partners LlcMajor ShareholderBuy200,000$15.00$3,000,000.00View SEC Filing  
3/29/2016Peter A ThompsonDirectorBuy550,000$15.00$8,250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corvus Pharmaceuticals (NASDAQ CRVS) News Headlines

Source:
DateHeadline
Corvus Pharmaceuticals (CRVS) Earns "Outperform" Rating from CowenCorvus Pharmaceuticals (CRVS) Earns "Outperform" Rating from Cowen
www.americanbankingnews.com - April 19 at 10:46 PM
Corvus Pharmaceuticals (CRVS) Price Target Cut to $17.00Corvus Pharmaceuticals (CRVS) Price Target Cut to $17.00
www.americanbankingnews.com - April 19 at 10:46 PM
 Analysts Expect Corvus Pharmaceuticals Inc (CRVS) to Post -$0.71 Earnings Per Share Analysts Expect Corvus Pharmaceuticals Inc (CRVS) to Post -$0.71 Earnings Per Share
www.americanbankingnews.com - April 5 at 3:17 PM
Corvus Pharmaceuticals (CRVS) Lifted to "Sell" at ValuEngineCorvus Pharmaceuticals (CRVS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - April 5 at 2:03 PM
Corvus Pharmaceuticals Inc (CRVS) Short Interest UpdateCorvus Pharmaceuticals Inc (CRVS) Short Interest Update
www.americanbankingnews.com - March 31 at 2:56 AM
ValuEngine Downgrades Corvus Pharmaceuticals (CRVS) to Strong SellValuEngine Downgrades Corvus Pharmaceuticals (CRVS) to Strong Sell
www.americanbankingnews.com - March 25 at 7:32 PM
Corvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by BrokeragesCorvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 1:44 AM
 Brokerages Expect Corvus Pharmaceuticals Inc (CRVS) Will Post Earnings of -$0.71 Per Share Brokerages Expect Corvus Pharmaceuticals Inc (CRVS) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - March 19 at 3:14 PM
Critical Comparison: Corvus Pharmaceuticals (CRVS) and Achieve Life Sciences (ACHV)Critical Comparison: Corvus Pharmaceuticals (CRVS) and Achieve Life Sciences (ACHV)
www.americanbankingnews.com - March 15 at 3:14 AM
Corvus Pharmaceuticals Inc (CRVS) Major Shareholder Adams Street Partners Llc Acquires 588,235 SharesCorvus Pharmaceuticals Inc (CRVS) Major Shareholder Adams Street Partners Llc Acquires 588,235 Shares
www.americanbankingnews.com - March 13 at 4:21 PM
Insider Buying: Corvus Pharmaceuticals Inc (CRVS) CEO Buys 100,000 Shares of StockInsider Buying: Corvus Pharmaceuticals Inc (CRVS) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - March 12 at 4:30 PM
Corvus Pharmaceuticals Announces Closing of Public Offering of Common StockCorvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 12 at 10:35 AM
Corvus Pharma (CRVS) Prices 7.06M Offering of Common Stock at $8.50/ShareCorvus Pharma (CRVS) Prices 7.06M Offering of Common Stock at $8.50/Share
www.streetinsider.com - March 8 at 5:06 PM
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common StockCorvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 8 at 10:04 AM
Equities Analysts Offer Predictions for Corvus Pharmaceuticals Incs Q1 2018 Earnings (CRVS)Equities Analysts Offer Predictions for Corvus Pharmaceuticals Inc's Q1 2018 Earnings (CRVS)
www.americanbankingnews.com - March 8 at 6:28 AM
Corvus Pharmaceuticals (CRVS) Stock Rating Lowered by Zacks Investment ResearchCorvus Pharmaceuticals (CRVS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 8:34 PM
Corvus Pharmaceuticals Inc (CRVS) Expected to Post FY2022 Earnings of ($2.21) Per ShareCorvus Pharmaceuticals Inc (CRVS) Expected to Post FY2022 Earnings of ($2.21) Per Share
www.americanbankingnews.com - March 7 at 4:19 PM
FY2018 EPS Estimates for Corvus Pharmaceuticals Inc (CRVS) Lowered by Cantor FitzgeraldFY2018 EPS Estimates for Corvus Pharmaceuticals Inc (CRVS) Lowered by Cantor Fitzgerald
www.americanbankingnews.com - March 7 at 11:48 AM
Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
finance.yahoo.com - March 6 at 9:31 AM
Corvus Pharmaceuticals (CRVS) Receives "Buy" Rating from CowenCorvus Pharmaceuticals (CRVS) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - March 2 at 4:22 PM
Corvus Pharmaceuticals (CRVS) Issues  Earnings Results, Beats Expectations By $0.18 EPSCorvus Pharmaceuticals (CRVS) Issues Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - March 2 at 11:39 AM
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateCorvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 1 at 4:39 PM
Corvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by AnalystsCorvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 1:52 AM
Reviewing Prosensa (RNA) & Corvus Pharmaceuticals (CRVS)Reviewing Prosensa (RNA) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - February 21 at 11:16 PM
Zacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per ShareZacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - February 13 at 7:16 PM
Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of "Hold" by BrokeragesCorvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumCorvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
finance.yahoo.com - February 1 at 9:06 AM
Comparing AC Immune (ACIU) & Corvus Pharmaceuticals (CRVS)Comparing AC Immune (ACIU) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - January 12 at 7:04 PM
Corvus Pharmaceuticals Inc (CRVS) Expected to Post Earnings of -$0.66 Per ShareCorvus Pharmaceuticals Inc (CRVS) Expected to Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - January 10 at 9:16 PM
Corvus Pharmaceuticals (CRVS) Downgraded by Zacks Investment Research to HoldCorvus Pharmaceuticals (CRVS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 5 at 7:02 PM
 Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - December 7 at 5:28 PM
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 SharesCorvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 Shares
www.americanbankingnews.com - November 22 at 4:53 PM
 Analysts Anticipate Corvus Pharmaceuticals, Inc. (CRVS) to Post -$0.66 EPS Analysts Anticipate Corvus Pharmaceuticals, Inc. (CRVS) to Post -$0.66 EPS
www.americanbankingnews.com - November 19 at 7:14 PM
Corvus Pharmaceuticals Is Now Oversold (CRVS)Corvus Pharmaceuticals Is Now Oversold (CRVS)
www.thestreet.com - November 14 at 10:59 PM
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient SelectionCorvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
finance.yahoo.com - November 11 at 10:36 PM
FY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by AnalystFY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by Analyst
www.americanbankingnews.com - November 8 at 9:51 AM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - November 7 at 8:26 PM
Corvus Pharmaceuticals, Inc. (CRVS) Posts  Earnings Results, Beats Expectations By $0.19 EPSCorvus Pharmaceuticals, Inc. (CRVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
www.americanbankingnews.com - November 3 at 5:48 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program Update
www.thestreet.com - November 2 at 6:30 PM
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program UpdateCorvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
finance.yahoo.com - November 2 at 6:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Short Interest UpdateCorvus Pharmaceuticals, Inc. (CRVS) Short Interest Update
www.americanbankingnews.com - October 28 at 1:26 AM
Oversold Conditions For Corvus Pharmaceuticals (CRVS)Oversold Conditions For Corvus Pharmaceuticals (CRVS)
www.thestreet.com - October 26 at 2:44 PM
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingCorvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - October 18 at 6:54 PM
Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - October 17 at 4:30 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment ResearchCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 11 at 12:04 AM
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceCorvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 6:20 PM
Contrasting Corvus Pharmaceuticals (CRVS) and The CompetitionContrasting Corvus Pharmaceuticals (CRVS) and The Competition
www.americanbankingnews.com - September 14 at 12:26 AM
Corvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per ShareCorvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
UPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to NeutralUPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to Neutral
www.streetinsider.com - August 24 at 5:43 PM
Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse GroupCorvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse Group
www.americanbankingnews.com - August 23 at 9:42 PM

SEC Filings

Corvus Pharmaceuticals (NASDAQ:CRVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corvus Pharmaceuticals (NASDAQ:CRVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corvus Pharmaceuticals (NASDAQ CRVS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.